西妥昔单抗联合XELOX化疗对不同K-ras基因型晚期结直肠癌的效果

Effect of Cetuximab Combined with XELOX Chemotherapy in the Treatment of Advanced Colorectal Cancer with Different K-ras Genotypes

目的:研究西妥昔单抗联合XELOX化疗对不同K-ras基因型晚期结直肠癌的临床效果。方法:前瞻性选取本院2018年1月-2019年1月收治的晚期结直肠癌患者64例,均进行K-ras基因检验并依据分型分组,野生型37例,突变型27例,均采取西妥昔单抗联合XELOX化疗。比较两组临床疗效、治疗前后Karnofsky评分(KPS)。结果:突变型组ORR为44.4%,DCR为92.6%,略高于野生型组的27.0%、75.7%,差异无统计学意义(P>0.05);两组治疗前及治疗4周期后KPS评分比较差异均无统计学意义(P>0.05)。结论:西妥昔单抗联合XELOX化疗治疗晚期结直肠癌K-ras野生型与突变型的临床效果相近,临床需结合晚期结直肠癌K-ras基因分型合理制定治疗方案。

Objective:To investigate the clinical effect of Cetuximab Combined with XELOX chemotherapy in the treatment of advanced colorectal cancer with different K-ras genotypes.Method:Sixty-four patients with advanced colorectal cancer admitted to our hospital from January 2018 to January 2019 were prospectively selected.All patients underwent K-ras gene test and were grouped according to type,including 37 patients with wild type and 27 patients with mutant type.All patients were treated with Cetuximab combined with XELOX chemotherapy.The clinical efficacy,Karnofsky score (KPS) before and after treatment were compared between the two groups.Result:The ORR of the mutant type group was 44.4%,and the DCR was 92.6%,which were slightly higher than 27.0% and 75.7% of the wild type group,the differences were not statistically significant (P>0.05);there were no significant differences in KPS scores between the two groups before and after 4 cycles of treatment (P>0.05).Conclusion:The clinical effect of Cetuximab combined with XELOX in the treatment of advanced colorectal cancer with K-ras wild type and mutant type is similar,so it is necessary to make a reasonable treatment plan combining with K-ras genotype of advanced colorectal cancer clinically.